Analyst Ratings

Upgrades, downgrades, and outlook changes from major analysts.

Coverage of analyst actions including upgrades, downgrades, initiations, and price-target changes. This category tracks how institutional research influences market perception, momentum shifts, and short-term price behavior.

Articles

3,519 total articles

DA Davidson Sticks With Buy on Crane NXT After Strong International Sales; Antares Vision Bid Faces Short Delay

DA Davidson Sticks With Buy on Crane NXT After Strong International Sales; Antares Vision Bid Faces Short Delay

DA Davidson reiterated a Buy rating and an $85.00 price target for Crane NXT (NYSE:CXT), citing sales that exceeded expectations, primarily driven by international Currency and DLRA segments. The target implies roughly 62% upside from the stock's current price of $52.53. While revenue and backlog metrics were encouraging, operating margins lagged D…

Cantor Fitzgerald Sticks With Overweight on Aurora Innovation, Sees Large Upside Despite Thin Revenues

Cantor Fitzgerald Sticks With Overweight on Aurora Innovation, Sees Large Upside Despite Thin Revenues

Cantor Fitzgerald has maintained an Overweight rating and a $12.00 price target on Aurora Innovation Inc (AUR), citing the company’s advances in autonomous trucking and partnerships to scale hardware. The target implies roughly 200% upside from the current share price of $4.06. Aurora has logged more than 4.5 million autonomous cumulative miles and…

DA Davidson Cuts Harley-Davidson Price Target as Inventory Reset and Weak Guidance Pressure Near-Term Outlook

DA Davidson Cuts Harley-Davidson Price Target as Inventory Reset and Weak Guidance Pressure Near-Term Outlook

DA Davidson lowered its price target for Harley-Davidson to $25.00 from $30.00 while maintaining a Buy rating after the company reported fourth-quarter 2025 results and issued 2026 guidance that fell short of expectations. Harley-Davidson’s revenue has fallen 13.76% over the past year, and analysts forecast another 17% sales decline for fiscal 2026…

Baird Sticks With Neutral on BioMarin After Rival’s Positive Trial, Flags Limited Near-Term Share Reaction

Baird Sticks With Neutral on BioMarin After Rival’s Positive Trial, Flags Limited Near-Term Share Reaction

Baird maintained a Neutral rating and a $65.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) after BridgeBio reported positive pivotal data for oral infigratinib in achondroplasia. Despite the competitive development, BioMarin’s fundamentals remain strong, with a Piotroski Score of 9, 12.39% revenue growth over the last year, and valua…

DA Davidson Sticks With Buy on Q2 Holdings, Sets $82 Target After Strong Q4 Revenue and EBITDA Beats

DA Davidson Sticks With Buy on Q2 Holdings, Sets $82 Target After Strong Q4 Revenue and EBITDA Beats

DA Davidson has reaffirmed a Buy rating on Q2 Holdings (QTWO) and set a $82.00 price target after the company reported fourth-quarter results that outpaced the firm's revenue and adjusted EBITDA forecasts. The target implies notable upside from the stock's prevailing price, while other brokers have trimmed price targets amid software sector valuati…

PayPay Seeks U.S. Listing as Nasdaq-Listed ADS, Files With SEC

PayPay Seeks U.S. Listing as Nasdaq-Listed ADS, Files With SEC

PayPay Corp has submitted a U.S. initial public offering filing with the Securities and Exchange Commission to list American Depositary Shares on the Nasdaq Global Select Market under the ticker PAYP. The filing discloses the company’s ownership stakes, recent quarterly revenue and earnings per share, annual payment volume, user penetration among s…

Barclays Keeps Overweight Call on CBRE, Sees Room for Double-Digit Growth; $192 Price Target Stands

Barclays Keeps Overweight Call on CBRE, Sees Room for Double-Digit Growth; $192 Price Target Stands

Barclays has reaffirmed an Overweight rating on CBRE Group with a $192.00 price target, noting robust operating-profit gains in advisory services and buildings operations & experience (BOE). The bank highlights management commentary pointing to a strong start to Q1 2026 with double-digit growth across all segments and expects that momentum to c…

BMO Cuts ICON Price Target to $100 Amid Ongoing Accounting Probe

BMO Cuts ICON Price Target to $100 Amid Ongoing Accounting Probe

BMO Capital reduced its 12-month price target on ICON plc (NASDAQ: ICLR) from $175.00 to $100.00 while keeping a Market Perform rating. The move follows an internal and external review into the company’s revenue recognition practices spanning fiscal 2023 through 2025, delayed financial reporting and withdrawn guidance. Multiple broker responses and…